The software group reported fourth quarter earnings per share (EPS) and revenue, which beat Wall Street expectations. Sales rose 23% year-on -year of US$772mln.
Meanwhile, AnaptysBio Inc (NASDAQ:ANAB) rose 8.79% in extended hours to US$123.83 after the drug developer announced positive peanut allergy treatment data yesterday.
AnaptysBio peanut allergy shot improves tolerance https://t.co/XbyyHOzYiC— Michael Blaiss, MD (@wheezemd) 27 March 2018
Analysis of the mid-stage trial data pointed to nearly half of patients treated showing peanut tolerance.
Concurrently, fellow drug maker Aimmune Therapeutics Inc (NASDAQ:AIMT) shares dropped. Aimmune's drug to treat peanut allergy in children succeeded in a late-stage study in February.
Meanwhile, SM Energy Co (NYSE:SM) nudged 0.27% to US$18.62 after the bell after the natural gas explorer said it had completed its previously announced sale of the majority of its assets in the Powder River Basin for US$500mln.
The company plans to use the proceeds for general corporate purposes, including to reduce debt.